

Supplemental Approvals

Generic Name (Trade Name—Company)

March 31, 2011

Uses/Notes

Adjunctive treatment of seizures associated with Lennox-Gastaut syndrome in patients 4 years of age and older

Rufinamide

(Banzel—Eisai)

New 40 mg/mL suspension

A 40 mg/mL oral suspension of [rufinamide](#) has been approved by FDA. This suspension is equivalent to the already available 200 mg and 400 mg rufinamide tablets on a mg-per-mg basis. The suspension should be dosed with the supplied calibrated oral dosing syringe and adapter. Key counseling points for patients using this new formulation include shaking the medication before each use, replacing the cap securely after opening, keeping the suspension in an upright position at room temperature, and using the product within 90 days of first opening the bottle.

Source URL:

<http://www.aphanet.org/new-40-mgml-suspension>

APhA DrugInfoLine is an official publication of, and is owned and copyrighted by the American Pharmacists Association, the national professional society of pharmacists. Materials in APhA DrugInfoLine do not necessarily represent the policy, recommendations, or endorsement of APhA. The publisher, authors, editors, reviewers, and contributors have taken care to ensure that information contained in APhA DrugInfoLine is accurate and current; however, they shall have no liability to any person or entity with regard to claims, losses, or damages caused or alleged to be caused, directly or indirectly, by use of any information contained in the publication. All decisions about drug therapy must be based on the independent judgment of the clinician. Copyright © 2000–2011, American Pharmacists Association. All rights reserved.